Wildeboer Dellelce LLP acted for CTI on the matter. Cytophage Technologies Ltd. (“Cytophage”), formerly Cuspis Capital III Ltd., has completed a reverse take-over (the “RTO”) of...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce LLP acted for the underwriters. HEALWELL AI Inc. (TSX: AIDX) completed a private placement of Class A subordinate voting shares of the Company for...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce acted for Origin Therapeutics Holdings Inc. on the matter. Origin Therapeutics Holdings Inc. has completed its reverse take-over transaction with Safe Supply Streaming Co...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce LLP acted for IberAmerican Lithium Inc. in connection with the RTO. IberAmerican Lithium Corp., formerly 1317198 B.C. Ltd., has completed a reverse take-over (the...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce LLP acted for IberAmerican in connection with the Offering. IberAmerican Lithium Inc., an Ontario based hard-rock lithium exploration company focused on advancing its 70%...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce represented Ridout & Maybee LLP on the matter. On August 17, 2023, IPH Limited and affiliates entered into a definitive agreement to acquire Intellectual...
You must be a Standard 1 Year member to access this content.
Wildeboer Dellelce LLP advised Lenworth on the deal. Trivest Partners L.P., a Miami-based private equity firm, through a wholly-owned subsidiary, completed the acquisition of all of...
You must be a Standard 1 Year member to access this content.
